comparemela.com

Palatin Technologies : Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 (Form 8-K)

Palatin Technologies : Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 (Form 8-K)

marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States ,America ,American ,Michaelb Raizman ,Paul Arndt ,Carl Spana ,Jamese Hattersley ,J Don Wang ,Prnewswire Palatin Technologies Inc ,Drug Administration ,Exchange Commission ,American Society Of Cataract ,Palatin Technologies Inc ,Product Development ,Securities Exchange ,Association For Research ,Business Development ,Ulcerative Colitis Currently Expected ,Start Next Quarter ,Top Line Results Expected ,Second Half Calendar ,Cash Equivalents ,Cash Runway Through Calendar ,Upcoming Events ,Autoimmune Programs ,New Drug Application ,American Society ,Refractive Surgery Annual ,Key Opinion Leader ,Retina Specialists ,Leadership Additions ,Chief Medical Officer ,Senior Vice President ,Vice President ,Hypoactive Sexual Desire Disorder ,Fiscal Year Ended ,North America ,Melanocortin Receptor Agonists ,Palatin Technologies ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Investor Inquiries ,Media Inquiries ,Lifesci Advisors ,Financial Statement Data Follows ,Months Ended June ,Ended June ,

comparemela.com © 2020. All Rights Reserved.